Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:11054 |
Name | urinary bladder cancer |
Definition | An urinary system cancer that results_in malignant growth located_in the urinary bladder. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5428 |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TSC1 loss | Sirolimus | urinary bladder cancer | sensitive | detail... |
TSC1 loss | Torin 1 | urinary bladder cancer | sensitive | detail... |
TSC1 loss | Luminespib + Sirolimus | urinary bladder cancer | sensitive | detail... |
TSC1 loss | Luminespib + Torin 1 | urinary bladder cancer | sensitive | detail... |
FGFR3 Y375C | Ponatinib | urinary bladder cancer | sensitive | detail... |
FGFR3 Y375C | Dovitinib | urinary bladder cancer | sensitive | detail... |
FGFR3 Y375C | Cediranib | urinary bladder cancer | resistant | detail... |
FGFR3 Y375C | Nintedanib | urinary bladder cancer | resistant | detail... |
FGFR3 Y375C | Brivanib | urinary bladder cancer | no benefit | detail... |
FGFR3 S249C | Ponatinib | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C | Dovitinib | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C | Cediranib | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C | Nintedanib | urinary bladder cancer | resistant | detail... |
FGFR3 S249C | Brivanib | urinary bladder cancer | no benefit | detail... |
FGFR3 wild-type | Ponatinib | urinary bladder cancer | resistant | detail... |
FGFR3 act mut | S-49076 | urinary bladder cancer | predicted - sensitive | detail... |
FGFR3 over exp | SU5402 | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C | Zoligratinib | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C | ASP5878 | urinary bladder cancer | sensitive | detail... |
HRAS mutant | Metformin | urinary bladder cancer | sensitive | detail... |
PTEN del | Metformin | urinary bladder cancer | sensitive | detail... |
TSC1 del | Metformin | urinary bladder cancer | sensitive | detail... |
FGFR3 mut FGFR3 over exp | Dovitinib | urinary bladder cancer | sensitive | detail... |
FGFR3 over exp | Dovitinib | urinary bladder cancer | sensitive | detail... |
FGFR3 over exp | Infigratinib | urinary bladder cancer | sensitive | detail... |
FGFR3 over exp | Dactolisib + Sorafenib | urinary bladder cancer | sensitive | detail... |
PIK3CA H1047R | Dactolisib | urinary bladder cancer | sensitive | detail... |
FGFR3 mutant | Fexagratinib | urinary bladder cancer | sensitive | detail... |
FGFR3 fusion | Fexagratinib | urinary bladder cancer | sensitive | detail... |
HRAS G12V | Binimetinib + Everolimus | urinary bladder cancer | sensitive | detail... |
HRAS G12V | Everolimus + Selumetinib | urinary bladder cancer | sensitive | detail... |
PIK3CA E545K | Pictilisib | urinary bladder cancer | sensitive | detail... |
PTEN N48I | Pictilisib | urinary bladder cancer | decreased response | detail... |
PIK3CA P124L PTEN del | Pictilisib | urinary bladder cancer | decreased response | detail... |
PIK3CA H1047R | Pictilisib | urinary bladder cancer | sensitive | detail... |
PIK3CA D549Y | Pictilisib | urinary bladder cancer | decreased response | detail... |
PIK3CA E545K | Cisplatin + Pictilisib | urinary bladder cancer | sensitive | detail... |
PIK3CA H1047R | Cisplatin + Pictilisib | urinary bladder cancer | sensitive | detail... |
PIK3CA E545K | Gemcitabine + Pictilisib | urinary bladder cancer | sensitive | detail... |
PIK3CA amp | Gemcitabine + Pictilisib | urinary bladder cancer | sensitive | detail... |
PIK3CA E545K | Pictilisib + Sorafenib | urinary bladder cancer | sensitive | detail... |
FGFR3 K652E | Derazantinib | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C | Cisplatin + Ipatasertib | urinary bladder cancer | predicted - sensitive | detail... |
FGFR3 S249C | Cisplatin + LY294002 | urinary bladder cancer | predicted - sensitive | detail... |
FGFR3 fusion | Regorafenib | urinary bladder cancer | sensitive | detail... |
HRAS G12V | ERAS-007 | urinary bladder cancer | sensitive | detail... |
NRAS Q61R | RAF265 | urinary bladder cancer | sensitive | detail... |
HRAS G12V | RAF265 | urinary bladder cancer | sensitive | detail... |
NRAS Q61L | RAF265 | urinary bladder cancer | sensitive | detail... |
NRAS Q61R | Trametinib | urinary bladder cancer | sensitive | detail... |
NRAS Q61R | RAF265 + Trametinib | urinary bladder cancer | sensitive | detail... |
HRAS G12V | RAF265 + Trametinib | urinary bladder cancer | sensitive | detail... |
NRAS Q61L | RAF265 + Trametinib | urinary bladder cancer | sensitive | detail... |
NRAS Q61R | LXH 254 | urinary bladder cancer | sensitive | detail... |
HRAS G12V | LXH 254 | urinary bladder cancer | sensitive | detail... |
NRAS Q61R | LXH 254 + Trametinib | urinary bladder cancer | sensitive | detail... |
FGFR3 K652E | PD173074 | urinary bladder cancer | resistant | detail... |
FGFR3 S249C | PD173074 | urinary bladder cancer | resistant | detail... |
FGFR3 S249C | 3D185 | urinary bladder cancer | sensitive | detail... |
FGFR3 amp | 3D185 | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C | TYRA-300 | urinary bladder cancer | predicted - sensitive | detail... |
FGFR3 K652E PIK3CA P124L | Alpelisib + Nintedanib | urinary bladder cancer | sensitive | detail... |
FGFR3 K652E PIK3CA P124L | Nintedanib + Pictilisib | urinary bladder cancer | sensitive | detail... |
PIK3CA E542Q PIK3CA E674Q | Alpelisib + Nintedanib | urinary bladder cancer | sensitive | detail... |
PIK3CA E542Q PIK3CA E674Q | Nintedanib + Pictilisib | urinary bladder cancer | sensitive | detail... |
FGFR3 R248C PIK3CA A1066V | Nintedanib + Pictilisib | urinary bladder cancer | sensitive | detail... |
FGFR3 Y373C | Pemigatinib | urinary bladder cancer | predicted - sensitive | detail... |
FGFR3 S249C | Erdafitinib + Quisinostat | urinary bladder cancer | sensitive | detail... |
PIK3CA A1066V | MK2206 | urinary bladder cancer | resistant | detail... |
PIK3CA P124L | MK2206 | urinary bladder cancer | resistant | detail... |
PIK3CA E545K | MK2206 | urinary bladder cancer | sensitive | detail... |
PIK3CA E545G | MK2206 | urinary bladder cancer | sensitive | detail... |
PIK3CA E542K PIK3CA E674Q | MK2206 | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C | Erdafitinib | urinary bladder cancer | sensitive | detail... |
FGFR3 Y373C | Erdafitinib | urinary bladder cancer | sensitive | detail... |
FGFR3 R248C | Erdafitinib | urinary bladder cancer | predicted - sensitive | detail... |
FGFR3 G370C | Erdafitinib | urinary bladder cancer | predicted - sensitive | detail... |
FGFR3 S249C | CPL304110 | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C FGFR3 V555M | Infigratinib | urinary bladder cancer | resistant | detail... |
FGFR3 S249C FGFR3 V555M | Pemigatinib | urinary bladder cancer | resistant | detail... |
FGFR3 S249C FGFR3 V555M | Erdafitinib | urinary bladder cancer | resistant | detail... |
FGFR3 S249C FGFR3 N540K | Pemigatinib | urinary bladder cancer | resistant | detail... |
FGFR3 S249C FGFR3 N540K | KIN-3248 | urinary bladder cancer | sensitive | detail... |
FGFR3 S249C FGFR3 V555M | KIN-3248 | urinary bladder cancer | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00313599 | Phase I | Lapatinib + Paclitaxel | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT00959868 | Phase I | Apatorsen | A Study for Treatment of Superficial Bladder Cancer Using OGX-427 | Unknown status | CAN | 0 |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01738815 | Phase I | Valproic acid | Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer | Completed | USA | 0 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | GBR | FIN | ESP | DNK | DEU | CAN | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 1 |
NCT01976741 | Phase I | Rogaratinib | Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor | Completed | USA | FRA | ESP | DEU | CHE | 2 |
NCT02030067 | Phase Ib/II | RX-3117 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | Completed | USA | 0 |
NCT02043665 | Phase I | Coxsackievirus A21 | Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) | Completed | USA | GBR | AUS | 0 |
NCT02091141 | Phase II | Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT02177695 | Phase II | Cisplatin + Gemcitabine Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine | S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer | Completed | USA | 0 |
NCT02323191 | Phase I | Atezolizumab + Emactuzumab | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | BEL | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | ISR | 0 |
NCT02351739 | Phase II | Pembrolizumab Acalabrutinib | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer | Completed | USA | 0 |
NCT02360618 | Phase II | Metformin + Simvastatin | Metformin and Simvastatin Use in Bladder Cancer | Unknown status | CAN | 0 |
NCT02365818 | Phase II | CG0070 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure | Completed | USA | 0 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | FRA | CAN | 0 |
NCT02529553 | Phase I | LY3076226 | A Study of LY3076226 in Participants With Advanced or Metastatic Cancer | Completed | USA | CAN | 0 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | POL | GBR | FRA | CAN | AUS | 2 |
NCT02605863 | Phase II | Enzalutamide | Enzalutamide for Bladder Cancer Chemoprevention | Terminated | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02675829 | Phase II | Ado-trastuzumab emtansine | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | Recruiting | USA | 0 |
NCT02753309 | Phase 0 | Sirolimus | A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer | Completed | USA | 0 |
NCT02808143 | Phase I | BCG solution + Pembrolizumab | Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer | Completed | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Completed | USA | 0 |
NCT03224182 | Phase III | Apaziquone | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Patients Undergoing TURBT | Terminated | USA | 0 |
NCT03294304 | Phase II | Cisplatin + Gemcitabine + Nivolumab | Nivolumab, Gemcitabine, and Cisplatin in Treatment of Bladder Cancer (MIBC) Undergoing Cystectomy | Completed | USA | 0 |
NCT03298958 | Phase III | Sirolimus | Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer | Withdrawn | USA | 0 |
NCT03319745 | Phase II | Pembrolizumab | A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy | Completed | USA | 0 |
NCT03330561 | Phase I | PRS-343 | PRS-343 in HER2-Positive Solid Tumors | Completed | USA | 0 |
NCT03333616 | Phase II | Ipilimumab + Nivolumab | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | Active, not recruiting | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT03519256 | Phase II | Linrodostat + Nivolumab Nivolumab BCG solution + Nivolumab BCG solution + Linrodostat + Nivolumab | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (CheckMate 9UT) | Terminated | USA | NLD | ITA | GBR | FRA | ESP | CAN | BRA | AUS | ARG | 5 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03637803 | Phase I | MRx0518 + Pembrolizumab | MRx0518 and Pembrolizumab Combination Study | Terminated | USA | 0 |
NCT03661320 | Phase III | Cisplatin + Gemcitabine + Nivolumab Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Linrodostat + Nivolumab | A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC | Active, not recruiting | USA | ROU | NZL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT03762161 | Phase II | Trifluridine-tipiracil hydrochloride | A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer | Unknown status | USA | 0 |
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | CAN | 0 |
NCT03872947 | Phase I | Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT03892642 | Phase Ib/II | Avelumab + BCG solution | Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer | Completed | USA | 0 |
NCT03915678 | Phase II | Atezolizumab + BDB001 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) | Recruiting | FRA | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04149691 | Phase I | CPL304110 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Recruiting | POL | 0 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | TUR | CAN | 2 |
NCT04179162 | Phase Ib/II | BCG solution + Gemcitabine | Bacillus Calmette-Guerin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment | Recruiting | USA | 0 |
NCT04209114 | Phase III | Nivolumab + NKTR-214 Nivolumab | A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer. | Completed | USA | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
NCT04241185 | Phase III | Pembrolizumab Cisplatin Mitomycin C Gemcitabine Fluorouracil | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LVA | ITA | ISR | HUN | GBR | FRA | EST | ESP | DNK | CZE | AUS | 8 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
NCT04383743 | Phase Ib/II | Cisplatin + Doxorubicin + Methotrexate + Pegfilgrastim + Pembrolizumab + Vinblastine | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | Active, not recruiting | USA | 0 |
NCT04387461 | Phase II | CG0070 + Dodecyl Maltoside + Pembrolizumab | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (Core-001) | Completed | USA | 1 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 1 |
NCT04424641 | Phase Ib/II | GEN1044 | A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors | Terminated | USA | ISR | ESP | DNK | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04452591 | Phase III | CG0070 + Dodecyl Maltoside | Study of CG0070 Given in Patients With Non-Muscular Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003) | Recruiting | USA | AUS | 3 |
NCT04482309 | Phase II | Trastuzumab deruxtecan | A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (DPT02) | Recruiting | USA | POL | NLD | ITA | GBR | ESP | CZE | CAN | BRA | BEL | AUS | 6 |
NCT04525131 | Phase II | CPX-POM | Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors | Completed | USA | 0 |
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT04690699 | Phase Ib/II | PVSRIPO + unspecified PD-1 antibody | LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04713891 | Phase I | KF-0210 Atezolizumab + KF-0210 | A Study of KF-0210 in Advanced Solid Tumors Patients | Completed | AUS | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |
NCT04851834 | Phase Ib/II | Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | Terminated | AUS | 0 |
NCT04902040 | Phase Ib/II | Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab + Plinabulin Atezolizumab + Avelumab + Durvalumab + Nivolumab + Pembrolizumab | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | Active, not recruiting | USA | 0 |
NCT04917809 | Phase II | Erdafitinib | A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | Recruiting | USA | 0 |
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05120622 | Phase Ib/II | Durvalumab + Tremelimumab | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (Rideau) | Withdrawn | CAN | 0 |
NCT05126472 | Phase I | 2141 V-11 | Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment | Recruiting | USA | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05259319 | Phase I | Atezolizumab + Tiragolumab | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) | Recruiting | FRA | 0 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05420636 | Phase II | ORY-1001 + Paclitaxel | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | Recruiting | USA | 0 |
NCT05512377 | Phase II | BI 907828 | Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Recruiting | USA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS | 7 |
NCT05581589 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | Recruiting | USA | 0 |
NCT05655598 | Phase I | Palbociclib + Pimitespib | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Withdrawn | USA | 0 |
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 0 |
NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Recruiting | USA | AUS | 0 |
NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05951179 | Phase Ib/II | TARA-002 | Dose Expansion, Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-2) | Recruiting | USA | CAN | 1 |
NCT06014502 | Phase I | IMGS-001 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06237920 | Phase II | Nivolumab Nivolumab + Relatlimab | Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab (TURANDORELA) | Recruiting | NLD | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
NCT06319820 | Phase III | Mitomycin C Gemcitabine Erdafitinib | A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1) | Recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | BRA | BEL | AUT | ARG | 4 |
NCT06567743 | Phase II | CG0070 + Dodecyl Maltoside | Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |